Frontiers in Oncology (May 2022)
An Extended Prognostic Index of the ISSWM Score Based on Thyroid Complications in Waldenström Macroglobulinemia/Lymphoplasmacytoid Lymphoma
- Xinting Hu,
- Xinting Hu,
- Xinting Hu,
- Xinting Hu,
- Hua Wang,
- Hua Wang,
- Dai Yuan,
- Dai Yuan,
- Dai Yuan,
- Dai Yuan,
- Dai Yuan,
- Dai Yuan,
- Huiting Qu,
- Huiting Qu,
- Huiting Qu,
- Huiting Qu,
- Huiting Qu,
- Huiting Qu,
- Ying Li,
- Ying Li,
- Ying Li,
- Ying Li,
- Ying Li,
- Ying Li,
- Na Wang,
- Na Wang,
- Na Wang,
- Na Wang,
- Na Wang,
- Na Wang,
- Xianghua Wang,
- Xianghua Wang,
- Xianghua Wang,
- Xianghua Wang,
- Xianghua Wang,
- Xianghua Wang,
- Xin Liu,
- Xin Liu,
- Xin Liu,
- Xin Liu,
- Xin Liu,
- Xin Liu,
- Hongzhi Xu,
- Hongzhi Xu,
- Hongzhi Xu,
- Hongzhi Xu,
- Hongzhi Xu,
- Hongzhi Xu,
- Ya Zhang,
- Ya Zhang,
- Ya Zhang,
- Ya Zhang,
- Xin Wang,
- Xin Wang,
- Xin Wang,
- Xin Wang,
- Xin Wang,
- Xin Wang
Affiliations
- Xinting Hu
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Xinting Hu
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Xinting Hu
- School of Medicine, Shandong University, Jinan, China
- Xinting Hu
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Hua Wang
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Hua Wang
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Dai Yuan
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Dai Yuan
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Dai Yuan
- School of Medicine, Shandong University, Jinan, China
- Dai Yuan
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Dai Yuan
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Dai Yuan
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Huiting Qu
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Huiting Qu
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Huiting Qu
- School of Medicine, Shandong University, Jinan, China
- Huiting Qu
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Huiting Qu
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Huiting Qu
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Ying Li
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Ying Li
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Ying Li
- School of Medicine, Shandong University, Jinan, China
- Ying Li
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Ying Li
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Ying Li
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Na Wang
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Na Wang
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Na Wang
- School of Medicine, Shandong University, Jinan, China
- Na Wang
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Na Wang
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Na Wang
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Xianghua Wang
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Xianghua Wang
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Xianghua Wang
- School of Medicine, Shandong University, Jinan, China
- Xianghua Wang
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Xianghua Wang
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Xianghua Wang
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Xin Liu
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Xin Liu
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Xin Liu
- School of Medicine, Shandong University, Jinan, China
- Xin Liu
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Xin Liu
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Xin Liu
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Hongzhi Xu
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Hongzhi Xu
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Hongzhi Xu
- School of Medicine, Shandong University, Jinan, China
- Hongzhi Xu
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Hongzhi Xu
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Hongzhi Xu
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Ya Zhang
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Ya Zhang
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Ya Zhang
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Ya Zhang
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Xin Wang
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Xin Wang
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Xin Wang
- School of Medicine, Shandong University, Jinan, China
- Xin Wang
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Xin Wang
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Xin Wang
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- DOI
- https://doi.org/10.3389/fonc.2022.870258
- Journal volume & issue
-
Vol. 12
Abstract
Waldenström macroglobulinemia/lymphoplasmacytoid lymphoma (WM/LPL) is a rare lymphoproliferative neoplasm characterized by clonally related lymphocytes, lymphoplasmacytic cells, and plasma cell proliferation. WM/LPL patients commonly present with elevated immunoglobulin, predominantly immunoglobulin M (IgM). Previous studies reported that thyroid dysfunction was associated with the development and progression of solid tumors. However, only limited information is available on the correlation between thyroid complications and lymphoid malignancies. The aim of our study was to explore the prognostic significance of thyroid complications in WM/LPL. Herein, 13.3% of WM/LPL patients were diagnosed with thyroid complications, which were significantly associated with unfavorable progression-free survival (PFS), overall survival (OS), and adverse treatment response. Co-existing thyroid disease was significantly related to alleviated serum IgM levels, providing an answer to practical problems. Furthermore, the presence of thyroid complications was identified as an independent prognostic indicator for PFS in WM/LPL. Incorporating the ISSWM score with thyroid complications was superior to ISSWM alone in risk stratification and prognostic prediction. Furthermore, subgroup analyses of WM/LPL patients revealed that subclinical hypothyroidism predicted undesirable outcomes at the early stage. These results were also supported by independent microarray dataset analyses. In conclusion, the primary strength of this study is that it provides robust real-world evidence on the prognostic role of thyroid complications, highlighting further clinical concerns in the management of WM/LPL patients.
Keywords
- Waldenström macroglobulinemia/lymphoplasmacytoid lymphoma
- thyroid complications
- survival
- immunoglobulin M
- retrospective
